CME
Latest Episodes
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Daratumumab/Lenalidomide/Dexamethasone (DRd)?
Host: Noa Biran, MD Host: Joseph Mikhael, MD Recognizing and treating early relapse of multiple myeloma (MM) is a challenge for healthcare professionals. This program is designed to improve clinicians ability to distinguish between relapse
Managing AE and Patient Intolerance With Combination Therapy in Early Relapse Multiple Myeloma
Host: Joseph Mikhael, MD Recognizing and treating early relapse of multiple myeloma (MM) is a challenge for healthcare professionals. This program is designed to improve clinicians ability to distinguish between relapse and progression of disea
Are There Other Novel Approaches or Targeted Therapies for Early Relapse?
Host: Noa Biran, MD Recognizing and treating early relapse of multiple myeloma (MM) is a challenge for healthcare professionals. This program is designed to improve clinicians ability to distinguish between relapse and progression of disease in
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Upfront ASCT and Lenalidomide Maintenance?
Host: Noa Biran, MD Host: Joseph Mikhael, MD Recognizing and treating early relapse of multiple myeloma (MM) is a challenge for healthcare professionals. This program is designed to improve clinicians ability to distinguish between relapse
Choosing and Sequencing Regimens in Relapsed Multiple Myeloma
Host: Joseph Mikhael, MD Recognizing and treating early relapse of multiple myeloma (MM) is a challenge for healthcare professionals. This program is designed to improve clinicians ability to distinguish between relapse and progression of disea
Multiple Myeloma At First Relapse: Is My Patient Refractory to Lenalidomide?
Host: Noa Biran, MD Recognizing and treating early relapse of multiple myeloma (MM) is a challenge for healthcare professionals. This program is designed to improve clinicians’ ability to distinguish between relapse and progression of disease in
Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma
Host: Jeffrey S. Weber, MD, PhD Host: Jason J. Luke, MD, FACP Host: Ryan Sullivan, MD Host: Omid Hamid, MD Approximately 50 - 60% of patients with melanoma have BRAF-activating tumors, meaning they are amenable to treatment with comb
Opening Statements in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Host: Jeffrey S. Weber, MD, PhD Host: Ryan Sullivan, MD Host: Omid Hamid, MD Approximately 50 - 60% of patients with melanoma have BRAF-activating tumors, meaning they are amenable to treatment with combination BRAF/MEK inhibitors. Howev
Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Host: Jeffrey S. Weber, MD, PhD Host: Ryan Sullivan, MD Host: Omid Hamid, MD Approximately 50 - 60% of patients with melanoma have BRAF-activating tumors, meaning they are amenable to treatment with combination BRAF/MEK inhibitors. Howev
Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma
Host: Omid Hamid, MD Host: Sapna Patel, MD Host: Ryan Sullivan, MD Host: Jeffrey S. Weber, MD, PhD Approximately 50 - 60% of patients with melanoma have BRAF-activating tumors, meaning they are amenable to treatment with combination
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast